TREATMENT-USE IDE COST-RECOVERY RESTRICTIONS WEIGHED BY FDA DUE TO COMMERCIALIZATION CONCERNS; AGENCY SEEKS COMMENTS ON SAFEGUARDS IN PROPOSED REG
This article was originally published in The Gray Sheet
Executive Summary
FDA's treatment-use investigational device exemption proposal may require additional cost recovery restrictions beyond those normally imposed on devices subject to IDEs in order to protect against commercialization of unapproved devices, the agency indicates in a Dec. 19 Federal Register notice announcing the proposed rule.
You may also be interested in...
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.